» Articles » PMID: 35933478

Developing Machine Learning Algorithms for Dynamic Estimation of Progression During Active Surveillance for Prostate Cancer

Overview
Journal NPJ Digit Med
Date 2022 Aug 6
PMID 35933478
Authors
Affiliations
Soon will be listed here.
Abstract

Active Surveillance (AS) for prostate cancer is a management option that continually monitors early disease and considers intervention if progression occurs. A robust method to incorporate "live" updates of progression risk during follow-up has hitherto been lacking. To address this, we developed a deep learning-based individualised longitudinal survival model using Dynamic-DeepHit-Lite (DDHL) that learns data-driven distribution of time-to-event outcomes. Further refining outputs, we used a reinforcement learning approach (Actor-Critic) for temporal predictive clustering (AC-TPC) to discover groups with similar time-to-event outcomes to support clinical utility. We applied these methods to data from 585 men on AS with longitudinal and comprehensive follow-up (median 4.4 years). Time-dependent C-indices and Brier scores were calculated and compared to Cox regression and landmarking methods. Both Cox and DDHL models including only baseline variables showed comparable C-indices but the DDHL model performance improved with additional follow-up data. With 3 years of data collection and 3 years follow-up the DDHL model had a C-index of 0.79 (±0.11) compared to 0.70 (±0.15) for landmarking Cox and 0.67 (±0.09) for baseline Cox only. Model calibration was good across all models tested. The AC-TPC method further discovered 4 distinct outcome-related temporal clusters with distinct progression trajectories. Those in the lowest risk cluster had negligible progression risk while those in the highest cluster had a 50% risk of progression by 5 years. In summary, we report a novel machine learning approach to inform personalised follow-up during active surveillance which improves predictive power with increasing data input over time.

Citing Articles

Machine Learning for Dynamic Prognostication of Patients With Hepatocellular Carcinoma Using Time-Series Data: Survival Path Versus Dynamic-DeepHit HCC Model.

Shen L, Jiang Y, Zhang T, Cao F, Ke L, Li C Cancer Inform. 2024; 23:11769351241289719.

PMID: 39421722 PMC: 11483769. DOI: 10.1177/11769351241289719.


A radiogenomic clinical decision support system to inform individualized treatment in advanced nasopharyngeal carcinoma.

Fang X, Zhong L, Jiang W, Huang C, Lei Y, Tang S iScience. 2024; 27(8):110431.

PMID: 39108708 PMC: 11301085. DOI: 10.1016/j.isci.2024.110431.


Seeing the random forest through the decision trees. Supporting learning health systems from histopathology with machine learning models: Challenges and opportunities.

Gonzalez R, Saha A, Campbell C, Nejat P, Lokker C, Norgan A J Pathol Inform. 2024; 15:100347.

PMID: 38162950 PMC: 10755052. DOI: 10.1016/j.jpi.2023.100347.


Comparison of MRI radiomics-based machine learning survival models in predicting prognosis of glioblastoma multiforme.

Zhang D, Luan J, Liu B, Yang A, Lv K, Hu P Front Med (Lausanne). 2023; 10:1271687.

PMID: 38098850 PMC: 10720716. DOI: 10.3389/fmed.2023.1271687.


Machine Learning Models for ASCVD Risk Prediction in an Asian Population - How to Validate the Model is Important.

Hsiao Y, Kuo C, Lin F, Wu Y, Lin T, Yeh H Acta Cardiol Sin. 2023; 39(6):901-912.

PMID: 38022427 PMC: 10646597. DOI: 10.6515/ACS.202311_39(6).20230528A.


References
1.
Venderbos L, Luiting H, Hogenhout R, Roobol M . Interaction of MRI and active surveillance in prostate cancer: Time to re-evaluate the active surveillance inclusion criteria. Urol Oncol. 2021; 41(2):82-87. DOI: 10.1016/j.urolonc.2021.08.008. View

2.
Liu Y, Hall I, Filson C, Howard D . Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. Urol Oncol. 2020; 39(7):432.e1-432.e10. PMC: 8374746. DOI: 10.1016/j.urolonc.2020.11.024. View

3.
Chen Q, Liu S, Lyu N, Jia Z, Chen M, Zhao M . Surveillance Strategy after Complete Ablation of Initial Recurrent Hepatocellular Carcinoma: A Risk-Based Machine Learning Study. J Vasc Interv Radiol. 2021; 32(11):1548-1557.e2. DOI: 10.1016/j.jvir.2021.07.025. View

4.
Caglic I, Sushentsev N, Gnanapragasam V, Sala E, Shaida N, Koo B . MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. Eur Radiol. 2020; 31(5):2696-2705. PMC: 8043947. DOI: 10.1007/s00330-020-07336-0. View

5.
Willemse P, Davis N, Grivas N, Zattoni F, Lardas M, Briers E . Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. Eur Urol. 2022; 81(4):337-346. DOI: 10.1016/j.eururo.2021.12.007. View